Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3-AIOKRK0306

D.P. Modest, V. Heinemann, G. Folprecht, T. Denecke, J. Pratschke, H.K. Lang, M. Bemelmans, T. Becker, M. Rentsch, D. Seehofer, C.J. Bruns, B. Gebauer, S. Held, A. Stahler, K. Heinrich, J.C. von Einem, S. Stintzing, U.P. Neumann, I. Ricard

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2389-2401
Number of pages13
JournalAnnals of Surgical Oncology
Volume27
Issue number7
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • 1st-line treatment
  • bevacizumab
  • chemotherapy
  • folfiri plus cetuximab
  • kras
  • liver metastases
  • open-label
  • randomized-trials
  • subgroup
  • therapy
  • 1ST-LINE TREATMENT
  • RANDOMIZED-TRIALS
  • BEVACIZUMAB
  • OPEN-LABEL
  • CHEMOTHERAPY
  • LIVER METASTASES
  • THERAPY
  • FOLFIRI PLUS CETUXIMAB
  • KRAS
  • SUBGROUP

Cite this